Overview of Dutasteride: Mechanism of Action and Clinical Applications

Dutasteride is a 5α-reductase inhibitor primarily used to treat benign prostatic hyperplasia (BPH). Its core function is to reduce the size of the prostate and improve urinary symptoms by inhibiting the conversion of testosterone to dihydrotestosterone (DHT). This article will focus on its mechanism of action, clinical efficacy, safety and manufacturer, focusing on analyzing its differences with the traditional drug finasteride, with authoritative data support.

Mechanism of action and drug characteristics

By inhibiting both type I and type II 5α-reductase, dutasteride reduces DHT levels more completely (up to more than 90%) than finasteride, which only inhibits type II. This feature makes it more effective in patients with larger prostates. Clinical trials show that after 6 months of medication, the prostate volume shrinks by about 30% on average, and the International Prostate Symptom Score (IPSS) improvement rate reaches 60%. Its half-life is as long as 5 weeks, and only a daily dose of 0.5 mg is required, but it needs to be taken continuously for 3-6 months to be effective.

Clinical efficacy and applicable population

Studies show that dutasteride is particularly suitable for patients with moderate to severe BPH. In a controlled trial involving 4,325 patients, it reduced the risk of acute urinary retention better than placebo (57% relative risk reduction). However, for patients with mild symptoms or prostate volume <30 mL, the guidelines recommend giving priority to α-blockers. It should be noted that this drug is not suitable for women and children, and may affect PSA test values ​​(requires correction).

Safety and common adverse reactions

The incidence of side effects of dutasteride is about 10%-15%, and the main manifestations are sexual dysfunction (such as loss of sexual desire, ejaculation disorder) and breast tenderness, but most symptoms are reversible after discontinuation of the drug. Concomitant use with alpha-blockers may increase the risk of orthostatic hypotension. The FDA black box warning indicates that it may increase the risk of high-grade prostate cancer, but follow-up studies believe that this association is not clear yet and that full evaluation is required before use.

Summary and production information

Taken together, dutasteride is an important choice for BPH treatment, especially for patients with significantly enlarged prostate. Its potent DHT-inhibiting ability results in significant symptom improvement, but this needs to be weighed against potential side effects. Currently major global manufacturers include GlaxoSmithKline (trade nameAvodart) and many generic drug companies. Please see the table below for specific product information:

Quote sources:
1. US FDA drug insert (Avodart)
2. "European Society of Urology BPH Treatment Guidelines" (2023 Edition)
3. Roehrborn CG, et al. Urology 2004 (pivotal clinical trial data)
4. National Medical Products Administration generic drug approval information